Ligand Pharmaceuticals Profit Margin

Ligand Pharmaceuticals (LGND) currently reports a profit margin of 63.49% as of June 2026. That compares with -40.44% in the prior-year period — up 257.0% year over year. That is above the Healthcare sector average of 14.34%. Use the charts on this page to explore Ligand Pharmaceuticals's profit margin history and peer comparisons.

Ligand Pharmaceuticals's profit margin increased from -40.44% to 63.49% — a 257.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ligand Pharmaceuticals's profit margin of 63.49% is higher than the Healthcare sector average of 14.34%. That is roughly 342.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Ligand Pharmaceuticals's current 63.49% should be judged against Healthcare norms (sector average: 14.34%) and against LGND's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 63.49%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Ligand Pharmaceuticals, and consider following LGND for alerts when major investors trade the stock.